by Jeff Kurzner | Jan 19, 2024 | Blog
Cyrano Therapeutics, Inc. announced that it has secured a $9.0 million Series B financing to advance the development of CYR-064 as a potential first-ever treatment for post-viral smell loss. Hyposmia, including post-viral hyposmia, is an increasingly prevalent and...